Education Intervention for Lung Cancer Screening Compliance

(QLC+ Trial)

NE
Overseen ByNicole Ezer, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Nicole Ezer, MD, FRCPC, MPH
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if educational materials can help individuals with untreated COPD (a lung condition that makes breathing difficult) or cardiovascular disease (heart-related issues) adhere to their medication plans more effectively over a year. Participants will be divided into groups based on whether they have COPD or cardiovascular disease. Eligible participants have been screened for lung cancer and either have untreated COPD or specific heart concerns identified through a CT scan. This trial suits those diagnosed with COPD who are not currently on the recommended treatment or those with a heart condition identified through lung cancer screening. As an unphased trial, it offers a unique opportunity to contribute to understanding how educational support can improve medication adherence.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it seems to focus on people who are not on certain recommended therapies, so you might not need to stop any current treatments.

What prior data suggests that this educational intervention is safe for patients with COPD and cardiovascular disease?

Research has shown that educational programs, like those in this trial, are generally safe. Studies have found that these programs help people manage chronic diseases such as COPD (a lung condition) and CVD (heart disease) without causing harm. Participants in past studies did not report any serious side effects from receiving educational materials and treatment advice.

Additionally, self-management programs, which often include educational components, have demonstrated positive results. These programs help people better manage their conditions, leading to fewer hospital visits. This suggests that the educational approach is safe and well-received by participants.

In this trial, the educational programs aim to assist patients and their healthcare providers in better managing conditions that often occur with lung cancer. While specific side effects or risks are not detailed, past experiences with similar programs support their safety and benefits.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores how educational interventions can boost compliance with lung cancer screening recommendations. Unlike traditional approaches that might focus solely on medical interventions, this trial emphasizes the power of informed decision-making by providing tailored educational materials and treatment recommendations to patients, general practitioners, and pharmacists. The unique aspect of this method is its holistic approach, aiming to bridge knowledge gaps and promote collaborative healthcare. By enhancing understanding and communication among all parties, this trial could lead to more proactive and effective lung cancer screenings, potentially catching conditions earlier and improving outcomes.

What evidence suggests that this educational intervention is effective for improving medication adherence in COPD and cardiovascular disease patients?

Research has shown that educational programs can help people better adhere to treatment plans for diseases like COPD (a lung disease) and CVD (heart disease). Studies have found that well-trained and informed healthcare providers can enhance their knowledge and practices, leading to improved patient health. Specifically, one study discovered that these educational efforts increased understanding of the disease and treatment adherence within just one year. Patients may be more likely to take their medications as prescribed when both they and their doctors are well-informed. In this trial, some participants will receive educational materials as part of the intervention arms for COPD and CVD. Additionally, incorporating these educational materials into existing programs, like lung cancer screenings, can amplify these benefits.12346

Are You a Good Fit for This Trial?

This trial is for individuals who have been screened for lung cancer and found to have mild to severe coronary artery calcification (CAC) without being on recommended lipid-lowering therapy, or diagnosed with symptomatic COPD not treated with first-line therapies. It's not suitable for those already on appropriate COPD treatment, without CAC, with known heart issues, diabetes, or a high suspicion of lung cancer.

Inclusion Criteria

I have COPD, experience symptoms, and am not on first-line treatment.
You have been screened for lung cancer using a low-dose CT scan of the chest as part of a specific project in Quebec.
I have mild to severe artery plaque and am not on cholesterol-lowering medication.

Exclusion Criteria

I don't have heart calcification, known heart disease, past heart surgery, or diabetes.
I am suspected to have lung cancer with a high-risk rating.
My COPD is either symptom-free or I am on the first line of treatment.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Educational intervention for untreated COPD and cardiovascular disease integrated in an existing lung cancer screening program

12 months
Regular visits as per intervention protocol

Follow-up

Participants are monitored for safety and effectiveness after intervention

12 months
Follow-up assessments at 6 and 12 months post intervention

What Are the Treatments Tested in This Trial?

Interventions

  • Educational material and treatment recommendations for patients, general practitioners and pharmacists
Trial Overview The study tests if providing educational materials and treatment recommendations can improve adherence to medication guidelines at 12 months in patients with untreated COPD and cardiovascular disease within a lung cancer screening program.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Active Control
Group I: Intervention Arm: CVDExperimental Treatment1 Intervention
Group II: Intervention Arm: COPDExperimental Treatment1 Intervention
Group III: Control Arm: CVDActive Control1 Intervention
Group IV: Control Arm: COPDActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Nicole Ezer, MD, FRCPC, MPH

Lead Sponsor

Trials
2
Recruited
430+

Published Research Related to This Trial

In a study of 1,078 COPD patients, only 40.4% had self-management plans, highlighting a significant gap in the implementation of recommended self-management support as per UK guidelines.
Patients with self-management plans were more likely to adhere to their medication, attend support groups, and have better knowledge about COPD, indicating that these plans are crucial for improving patient outcomes.
Self-management behaviour and support among primary care COPD patients: cross-sectional analysis of data from the Birmingham Chronic Obstructive Pulmonary Disease Cohort.Khan, A., Dickens, AP., Adab, P., et al.[2022]
The Global Initiative for Chronic Obstructive Lung Disease Report emphasizes the importance of proper management and prevention strategies for COPD, particularly in older adults who are most affected by this condition.
Pharmacists play a crucial role in improving COPD management by providing counseling on medication selection, educating patients about the disease, ensuring adherence to treatment, and teaching proper inhaler techniques.
Chronic Obstructive Pulmonary Disease, Part 2: A Review of Pharmacotherapy Options.Naberhaus, T.[2023]
A study involving 18 general practices in Poland will evaluate a tailored implementation strategy aimed at improving general practitioners' adherence to COPD management guidelines, focusing on four key recommendations.
The trial will compare the effectiveness of these tailored interventions against usual care over a nine-month period, with the primary outcome being adherence to recommendations such as smoking cessation advice and proper inhaler use.
Evaluation of a tailored implementation strategy to improve the management of patients with chronic obstructive pulmonary disease in primary care: a study protocol of a cluster randomized trial.Godycki-Cwirko, M., Zakowska, I., Kosiek, K., et al.[2021]

Citations

NCT05444062 | Quebec Lung Cancer Screening PLUS TrialA randomized controlled trial of an educational intervention for untreated chronic obstructive pulmonary disease (COPD) and/or cardiovascular disease (CVD).
Educational interventions for health professionals managing ...Studies have shown beneficial effects of training and education on health professional knowledge and practices surrounding COPD diagnosis and treatment. A four‐ ...
Effects of an integrated care intervention on risk factors ...This IC trial improved disease knowledge, and treatment adherence, after 1 year of intervention, suggesting that these factors may play a role in the prevention ...
Educational interventions for health professionals managing ...Improving knowledge and skills related to optimal COPD management amongst all health professionals practising in primary care could further ...
Lung cancer screening in patients with chronic obstructive ...Patients with COPD included in lung cancer screening programs could also benefit from other interventions, such as smoking cessation and adequate treatment.
GOLD-2025-Report-v1.0-15Nov2024_WMV.pdfSystematic reviews have provided evidence that self-management interventions improve outcomes in COPD. A 2022. Cochrane review reported that ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security